Halda Therapeutics
New Haven, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $126M
Overview
Developing next-generation targeted protein degraders for oncology.
Oncology
Technology Platform
A proprietary platform for discovering molecular glue degraders that induce novel protein-protein interactions to co-opt the ubiquitin-proteasome system for targeted protein degradation.
Funding History
1Total raised:$126M
Venture$126M
Opportunities
Potential to unlock a new wave of targeted cancer therapies against historically undruggable proteins.
Risk Factors
High technical risk in demonstrating clinical efficacy and safety for a novel modality still in its early industrial application.
Competitive Landscape
Competes with established TPD companies like Arvinas and Nurix, as well as large pharma, but differentiates through a focus on novel molecular glue degraders.